Guided Therapeutics (GTHP) Total Debt Growth (1y) (2011 - 2026)
Guided Therapeutics (GTHP) Total Debt Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | 142.67% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -9.88% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -1.95% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 1,188.16% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | 0.12% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -17.79% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -9.03% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -0.50% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | 51.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.43% |
| Dec 31, 2025 | -51.06% |
| Sep 30, 2025 | -97.55% |
| Jun 30, 2025 | -97.06% |
| Mar 31, 2025 | 70.81% |
| Sep 30, 2024 | 1,156.48% |
| Jun 30, 2024 | 111.19% |
| Mar 31, 2024 | 5.42% |
| Sep 30, 2023 | -91.34% |
| Jun 30, 2023 | 636.31% |
| Mar 31, 2023 | -15.67% |
| Dec 31, 2022 | -89.18% |
| Sep 30, 2022 | 35.03% |
| Jun 30, 2022 | -91.38% |
| Mar 31, 2022 | -95.63% |
| Dec 31, 2021 | 93.18% |
| Sep 30, 2021 | 1,510.00% |
| Jun 30, 2021 | 51.88% |
| Mar 31, 2021 | 7.11% |
| Dec 31, 2020 | -38.14% |